ClinicalTrials.gg
RecruitingNCT07335497ASCENDUpdated Nov 13, 2026

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1/2 interventional study of CR-001 and Paclitaxel in Locally Advanced / Metastatic Solid Tumors, sponsored by Crescent Biopharma, Inc.. Recruiting at 36 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Crescent Biopharma, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 13, 2026First sites in France and UkraineEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
540
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 345 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
106th of 1,866
540 · median 43
Started
2026
with 85 others
Phase 1/2
268 of 2,057
63 open now
Primary completion
2029-02
later than 455 of 542 live
Registered
1,992nd of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 106th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 86 that started in 2026, is one of 268 in phase 1/2, reaches primary completion later than 455 of the 542 other live ones, and was the 1,992nd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

345 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Read the detailed description

The study will be 4 parts: dose escalation, backfill, dose expansion and dose optimization cohorts. The study will follow a stepwise approach, beginning with a typical dose escalation in participants with selected indications of advanced solid tumors. Additional participants will enroll in the backfill part at select dose levels that have been previously cleared for safety by the safety review committee. Dose expansion will enroll 7 cohorts of participants who will receive CR-001 in combination with chemotherapy. In dose optimization, participants will be randomized to one of two CR-001 dose levels.

All participants will undergo a screening period, a treatment period of up to 2 years, a safety follow-up period, and long-term efficacy and survival follow-up. During the treatment period, participants will undergo clinical and safety assessments including disease assessment scans and blood laboratory safety, pharmacokinetic, and pharmacodynamic assessments. After treatment ends, disease scans will continue until disease progression, and long-term follow-up visits will be conducted by telephone every 3 months.

03

Conditions studied

  • Locally Advanced / Metastatic Solid Tumors

Browse trials for

Keywords

  • solid tumors
  • metastatic
  • VEGF
  • PD-1
  • anti-PD-1
  • anti VEGF
  • immuno-oncology
  • anti-angiogenic therapy
  • checkpoint inhibitor
  • metastatic cancer
  • advanced cancer
  • First-in-Human
  • Dose Escalation
  • Dose Optimization
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • ≥ 3 months
  • (ECOG) performance status score of 0 - 1
  • Adequate organ function and hematologic reserve based on laboratory parameters
  • Have defined by v1.1
  • For Backfill, Dose Expansion and Dose Optimization: Willingness to provide recent sample or willingness to undergo biopsy
  • Tumor Indication specific inclusion criteria:
  • For dose escalation or backfill: progressing from, intolerant to, or ineligible for (due to unavailability or ) local standard of care therapies and have one of the following locally advanced or tumor types:

    • Non-small cell lung cancer (NSCLC)
    • Hepatocellular carcinoma (HCC)
    • Biliary tract cancer (BTC)
    • Endometrial carcinoma
    • Cervical cancer
    • Ovarian cancer
    • Gastric or gastroesophageal cancer (GC/GEJ)
    • Colorectal cancer (CRC)
  • For dose expansion: have one of the following locally advanced or metastatic tumor types:

    • 1L Non-small cell lung cancer (NSCLC)
    • 1L Colorectal cancer (CRC)
    • 3L Colorectal cancer (CRC)
    • 1L Endometrial carcinoma
    • 1L Gastric or gastroesophageal cancer (GC/GEJ)
    • 2L Gastric or gastroesophageal cancer (GC/GEJ)
    • 1L Biliary tract cancer (BTC)

Key Exclusion Criteria for all parts

  • Has other than disease under study within the past 3 years
  • Has conditions requiring treatment with or increasing doses of systemic therapy
  • Has not adequately recovered from recent major surgery
  • Has ongoing clinically significant toxicity related to prior therapy
  • Has active central nervous system (CNS) metastases
  • Has active disease requiring systemic therapy in the past 2 years (replacement therapy is permitted)
  • Has a history of serious Grade ≥ 3 immune-related adverse event (irAE)
  • Has a history of noninfectious pneumonitis/interstitial lung disease
  • Has an active severe infection
  • Has received a live or attenuated vaccine within 30 days of the first dose
  • Has undergone prior allogeneic stem cell or solid organ transplantation
  • Has protocol-specified events related to gastrointestinal perforation, surgery, wound healing complications, and bleeding
  • Has clinically significant cardiovascular disease

Key Exclusion Criteria for dose expansion only

  • Has received prior /L1 treatment
  • Has history of reaction to the cohort-specific combination agent(s) or its
  • Has any contraindication to the cohort-specific combination agent(s)
  • Has Grade >1 neuropathy at Screening NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    CR-001 Dose escalation

    Escalating dose levels of CR-001 to define the maximum tolerated dose of CR-001 in participants with locally advanced or metastatic solid tumors who are refractory to or unable to tolerate standard of care treatment, or for whom standard of care treatment is unavailable

    Drug: CR-001

  • Experimental
    CR-001 Backfill

    Escalating dose levels of CR-001 Indication-specific cohort populations will be tested

    Drug: CR-001

  • Experimental
    CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer

    CR-001 in combination with paclitaxel or pemetrexed + carboplatin

    Drug: CR-001 · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Carboplatin

  • Experimental
    CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer

    CR-001 in combination with FOLFOX

    Drug: CR-001 · Drug: FOLFOX

  • Experimental
    CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer

    CR-001 in combination with trifluridine + tipiracil

    Drug: CR-001 · Drug: trifluridine and tipiracil

  • Experimental
    CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma

    CR-001 in combination with paclitaxel + carboplatin

    Drug: CR-001 · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer

    CR-001 in combination capecitabine + oxaliplatin

    Drug: CR-001 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer

    CR-001 in combination with paclitaxel

    Drug: CR-001 · Drug: Paclitaxel

  • Experimental
    CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer

    CR-001 in combination with gemcitabine + cisplatin

    Drug: CR-001 · Drug: Gemcitabin · Drug: Cisplatin

  • Experimental
    CR-001 Dose Optimization Cohort X

    monotherapy dose level (DL)-X Indication-specific cohort populations will be tested

    Drug: CR-001

  • Experimental
    CR-001 Dose Optimization Cohort Y

    monotherapy dose level (DL)-Y Indication-specific cohort populations will be tested

    Drug: CR-001

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicities

    Per cohort

    Time frame: From the first dose of study drug up until approximately 1 month

  2. Part 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicable

    Per Cohort

    Time frame: From the first dose of study drug up until approximately 1 month

  3. All parts - Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment - emergent serious adverse events

    Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    Time frame: From the first dose of study drug until 90 days after the last dose of study drug

  4. All parts - Incidence and severity of TEAEs leading to dose modifications

    Time frame: From the first dose of study drug until 90 days after the last dose of study drug

  5. All parts - Incidence and severity of TEAEs leading to treatment discontinuation

    Time frame: From the first dose of study drug until 90 days after the last dose of study drug

  6. Part 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)

    Time frame: From the first dose of study drug until 90 days after the last dose of study drug

Secondary outcomes

  1. All parts - Determination of recommended Phase 2 dose(s)

    Time frame: From the first dose of study drug until 90 days after the last dose of study drug

  2. All parts - Serum CR-001 pharmacokinetic parameters

    AUC0--inf after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  3. All parts - Serum CR-001 pharmacokinetic parameters

    AUClast after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  4. All parts - Serum CR-001 pharmacokinetic parameters

    Cmax after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  5. All parts - Serum CR-001 pharmacokinetic parameters

    Tmax after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  6. All parts - Serum CR-001 pharmacokinetic parameters

    Vd after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  7. All parts - Serum CR-001 pharmacokinetic parameters

    CL after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  8. All parts - Serum CR-001 pharmacokinetic parameters

    t½ after a single dose and steady state parameters, as appropriate

    Time frame: Predose until up to approximately 36 months

  9. All parts - Incidence of participants with detectable antidrug antibodies

    Time frame: Predose until up to approximately 36 months

  10. Parts 1, 2 and 4 - Overall response rate

    Time frame: From the first dose of study drug until up to approximately 36 months

  11. Parts 1, 2 and 4 - Duration of response

    Time frame: From the first dose of study drug until up to approximately 36 months

  12. Parts 1, 2 and 4 - Time to response

    Time frame: From the first dose of study drug until up to approximately 36 months

  13. Parts 1, 2 and 4 - Progression free survival

    Time frame: From the first dose of study drug until up to approximately 36 months

  14. Parts 1, 2 and 4 - Overall survival

    Time frame: From the first dose of study drug until up to approximately 36 months

  15. Parts 1, 2 and 4 - Best percent change in target lesions

    Time frame: From the first dose of study drug until up to approximately 36 months

  16. Part 3 (Dose Expansion) - DOR, DCR, TTR, PFS, OS, and best percentage change in target lesions

    Time frame: From the first dose of study drug until up to approximately 36 months

07

Study locations

35 of 36 sites recruiting
  • Clinical Study Site
    Birmingham, Alabama 35294, United States
    Recruiting
  • Clinical Study Site
    Los Angeles, California 90033, United States
    Recruiting
  • Clinical Study Site
    Denver, Colorado 80218, United States
    Recruiting
  • Clinical Study Site
    Washington D.C., District of Columbia 20009, United States
    Recruiting
  • Clinical Study Site
    Orlando, Florida 32827, United States
    Recruiting
  • Clinical Study Site
    Sarasota, Florida 34236, United States
    Recruiting
  • Clinical Study Site
    Detroit, Michigan 48201, United States
    Recruiting
  • Clinical Study Site
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Clinical Study Site
    New York, New York 10029, United States
    Recruiting
  • Clinical Study Site
    Columbus, Ohio 43210, United States
    Recruiting
  • Clinical Study Site
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Clinical Study Site
    Nashville, Tennessee 37203, United States
    Recruiting
  • Clinical Study Site
    Dallas, Texas 75230, United States
    Recruiting
  • Clinical Study Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Clinical Study Site
    West Valley City, Utah 84119, United States
    Recruiting
  • Clinical Study Site
    South Brisbane, Queensland 4101, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Clinical Study Site
    Villejuif, 94805, France
    Recruiting
  • Clinical Study Site
    Dublin, Ireland, Ireland
    Recruiting
  • Clinical Study Site
    Milan, Milano 20089, Italy
    Recruiting
  • Clinical Study Site
    Candiolo, Torino 10060, Italy
    Recruiting
  • Clinical Study Site
    Florence, 50134, Italy
    Recruiting
  • Clinical Study Site
    Cluj-Napoca, Cluj 400015, Romania
    Recruiting
  • Clinical Study Site
    Bucharest, 022328, Romania
    Recruiting
  • Clinical Study Site
    Seoul, Seoul 03080, South Korea
    Recruiting
  • Clinical Study Site
    Seoul, Seoul 03722, South Korea
    Recruiting
  • Clinical Study Site
    Seoul, Seoul 06351, South Korea
    Recruiting
  • Clinical Study Site
    Songpa-dong, Seoul 05505, South Korea
    Recruiting
  • Clinical Study Site
    Seongnam-si, 13620, South Korea
    Recruiting
  • Clinical Study Site
    Barcelona, Barcelona 08023, Spain
    Recruiting
  • Clinical Study Site
    Logroño, La Rioja 26006, Spain
    Recruiting
  • Clinical Study Site
    Madrid, Madrid 28040, Spain
    Recruiting
  • Clinical Study Site
    Madrid, Madrid 28223, Spain
    Recruiting
  • Clinical Study Site
    Kyiv, 01135, Ukraine
    Recruiting
  • Clinical Study Site
    Manchester, Greater Manchester M20 4 BX, United Kingdom
    Recruiting
  • Clinical Study Site
    Hampstead, NW3 2QG, United Kingdom
    Recruiting
  • Clinical Study Site
    London, SE1 2PR, United Kingdom
    Recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 36 months is below that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 13, 2026
StartActual
Feb 17, 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 16 sites removed — first sites in France and Ukraine
Show 21 added (6 South Korea, 6 Spain, 3 Italy, 2 Ireland, 2 United Kingdom, 1 France, 1 Ukraine)
  • Clinical Study Site · Villejuif, France
  • Clinical Study Site · Dublin, Ireland
  • Clinical Study Site · Florence, Italy
  • Clinical Study Site · Milan, Italy
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Barcelona, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · London, United Kingdom
  • Clinical Study Site · Dublin, Ireland
  • Clinical Study Site · Milan, Italy
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Barcelona, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Kyiv, Ukraine
  • Clinical Study Site · Hampstead, United Kingdom
Show 16 removed
  • Clinical Study Site · Dublin, Ireland
  • Clinical Study Site · Milan, Italy
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Barcelona, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Dublin, Ireland
  • Clinical Study Site · Milan, Italy
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Seoul, South Korea
  • Clinical Study Site · Barcelona, Spain
  • Clinical Study Site · Madrid, Spain
  • Clinical Study Site · Madrid, Spain
across 2 updates, Oct 20, 2026 – Nov 13, 2026
Enrollment
290→540
Oct 20, 2026
Eligibility
8 criteria edited, 13 added
What changed in the criteria
  • EditedFor Backfill, Dose Expansion and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
  • EditedNon-small cell lung cancer (NSCLC)
  • EditedHepatocellular carcinoma (HCC)
  • EditedBiliary tract cancer (BTC)
  • EditedGastric or gastroesophageal cancer (GC/GEJ)
  • EditedColorectal cancer (CRC)
  • AddedFor dose expansion: have one of the following locally advanced or metastatic tumor types:
  • Added1L Non-small cell lung cancer (NSCLC)
  • Added1L Colorectal cancer (CRC)
  • Added3L Colorectal cancer (CRC)
  • Added1L Endometrial carcinoma
  • Added1L Gastric or gastroesophageal cancer (GC/GEJ)
  • Added2L Gastric or gastroesophageal cancer (GC/GEJ)
  • Added1L Biliary tract cancer (BTC)
  • EditedKey Exclusion Criteria for all parts
  • AddedHas clinically significant cardiovascular disease
  • AddedKey Exclusion Criteria for dose expansion only
  • AddedHas received prior anti-PD-1/L1 treatment
  • AddedHas history of hypersensitivity reaction to the cohort-specific combination agent(s) or its excipients
  • AddedHas any contraindication to the cohort-specific combination agent(s)
  • EditedHas clinically significant cardiovascular diseaseGrade >1 neuropathy at Screening NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
Oct 20, 2026
Interventions
Added Drug: Paclitaxel·Drug: trifluridine and tipiracil·Drug: Pemetrexed·Drug: Carboplatin·Drug: Oxaliplatin·and 4 more
All 9

Drug: Paclitaxel · Drug: trifluridine and tipiracil · Drug: Pemetrexed · Drug: Carboplatin · Drug: Oxaliplatin · Drug: Gemcitabin · Drug: Cisplatin · Drug: Capecitabine · Drug: FOLFOX

. Arms added: CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer·CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer·CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer·CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma·CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer·and 2 more
All 7

CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer · CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer · CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer · CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma · CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer

Oct 20, 2026
Primary outcomes
2 edited, 1 added
What changed in the outcomes
  • EditedPart 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
  • EditedPart 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
  • AddedPart 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: From the first dose of study drug until 90 days after the last dose of study drug
Oct 20, 2026
Secondary outcomes
6 edited, 1 added
What changed in the outcomes
  • EditedAll partsParts 1, 2 and 4 - Overall response rateTime frame: From the first dose of study drug until up to approximately 36 months
  • EditedAll partsParts 1, 2 and 4 - Duration of responseTime frame: From the first dose of study drug until up to approximately 36 months
  • EditedAll partsParts 1, 2 and 4 - Time to responseTime frame: From the first dose of study drug until up to approximately 36 months
  • EditedAll partsParts 1, 2 and 4 - Progression free survivalTime frame: From the first dose of study drug until up to approximately 36 months
  • EditedAll partsParts 1, 2 and 4 - Overall survivalTime frame: From the first dose of study drug until up to approximately 36 months
  • EditedAll partsParts 1, 2 and 4 - Best percent change in target lesionsTime frame: From the first dose of study drug until up to approximately 36 months
  • AddedPart 3 (Dose Expansion) - DOR, DCR, TTR, PFS, OS, and best percentage change in target lesionsTime frame: From the first dose of study drug until up to approximately 36 months
Oct 20, 2026
Show all 2 updates
  1. Nov 13, 2026
    10 sites added, 8 sites removed — first site in Ukraine
    Show 10 added (3 South Korea, 3 Spain, 1 Ireland, 1 Italy, 1 Ukraine, 1 United Kingdom)
    • Clinical Study Site · Dublin, Ireland
    • Clinical Study Site · Milan, Italy
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Barcelona, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · Kyiv, Ukraine
    • Clinical Study Site · Hampstead, United Kingdom
    Show 8 removed
    • Clinical Study Site · Dublin, Ireland
    • Clinical Study Site · Milan, Italy
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Barcelona, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · Madrid, Spain
    + 1 other change: verification date
  2. Oct 20, 2026
    11 sites added, 8 sites removed — first site in France
    Show 11 added (3 South Korea, 3 Spain, 2 Italy, 1 France, 1 Ireland, 1 United Kingdom)
    • Clinical Study Site · Villejuif, France
    • Clinical Study Site · Dublin, Ireland
    • Clinical Study Site · Florence, Italy
    • Clinical Study Site · Milan, Italy
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Barcelona, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · London, United Kingdom
    Show 8 removed
    • Clinical Study Site · Dublin, Ireland
    • Clinical Study Site · Milan, Italy
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Seoul, South Korea
    • Clinical Study Site · Barcelona, Spain
    • Clinical Study Site · Madrid, Spain
    • Clinical Study Site · Madrid, Spain
    Enrollment 290→540
    Eligibility 8 criteria edited, 13 added
    What changed in the criteria
    • EditedFor Backfill, Dose Expansion and Dose Optimization: Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy
    • EditedNon-small cell lung cancer (NSCLC)
    • EditedHepatocellular carcinoma (HCC)
    • EditedBiliary tract cancer (BTC)
    • EditedGastric or gastroesophageal cancer (GC/GEJ)
    • EditedColorectal cancer (CRC)
    • AddedFor dose expansion: have one of the following locally advanced or metastatic tumor types:
    • Added1L Non-small cell lung cancer (NSCLC)
    • Added1L Colorectal cancer (CRC)
    • Added3L Colorectal cancer (CRC)
    • Added1L Endometrial carcinoma
    • Added1L Gastric or gastroesophageal cancer (GC/GEJ)
    • Added2L Gastric or gastroesophageal cancer (GC/GEJ)
    • Added1L Biliary tract cancer (BTC)
    • EditedKey Exclusion Criteria for all parts
    • AddedHas clinically significant cardiovascular disease
    • AddedKey Exclusion Criteria for dose expansion only
    • AddedHas received prior anti-PD-1/L1 treatment
    • AddedHas history of hypersensitivity reaction to the cohort-specific combination agent(s) or its excipients
    • AddedHas any contraindication to the cohort-specific combination agent(s)
    • EditedHas clinically significant cardiovascular diseaseGrade >1 neuropathy at Screening NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.
    Primary outcomes 2 edited, 1 added
    What changed in the outcomes
    • EditedPart 1 (Dose Escalation) - Incidence and nature of dose-limiting toxicitiesTime frame: From the first dose of study drug up until approximately 1 month
    • EditedPart 1 (Dose Escalation) - Characterization of the maximum tolerated dose, if applicableTime frame: From the first dose of study drug up until approximately 1 month
    • AddedPart 3 (Dose Expansion) - Overall response rate (ORR) by Investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)Time frame: From the first dose of study drug until 90 days after the last dose of study drug
    Secondary outcomes 6 edited, 1 added
    What changed in the outcomes
    • EditedAll partsParts 1, 2 and 4 - Overall response rateTime frame: From the first dose of study drug until up to approximately 36 months
    • EditedAll partsParts 1, 2 and 4 - Duration of responseTime frame: From the first dose of study drug until up to approximately 36 months
    • EditedAll partsParts 1, 2 and 4 - Time to responseTime frame: From the first dose of study drug until up to approximately 36 months
    • EditedAll partsParts 1, 2 and 4 - Progression free survivalTime frame: From the first dose of study drug until up to approximately 36 months
    • EditedAll partsParts 1, 2 and 4 - Overall survivalTime frame: From the first dose of study drug until up to approximately 36 months
    • EditedAll partsParts 1, 2 and 4 - Best percent change in target lesionsTime frame: From the first dose of study drug until up to approximately 36 months
    • AddedPart 3 (Dose Expansion) - DOR, DCR, TTR, PFS, OS, and best percentage change in target lesionsTime frame: From the first dose of study drug until up to approximately 36 months
    Interventions Added Drug: Paclitaxel·Drug: trifluridine and tipiracil·Drug: Pemetrexed·Drug: Carboplatin·Drug: Oxaliplatin·and 4 more
    All 9

    Drug: Paclitaxel · Drug: trifluridine and tipiracil · Drug: Pemetrexed · Drug: Carboplatin · Drug: Oxaliplatin · Drug: Gemcitabin · Drug: Cisplatin · Drug: Capecitabine · Drug: FOLFOX

    . Arms added: CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer·CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer·CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer·CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma·CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer·and 2 more
    All 7

    CR-001 Dose Expansion 3A: First-line (1L) Non-small cell lung cancer · CR-001 Dose Expansion 3B: First-line (1L) colorectal cancer · CR-001 Dose Expansion 3C: Third-line (3L) colorectal cancer · CR-001 Dose Expansion 3D: First-line (1L) endometrial carcinoma · CR-001 Dose Expansion 3E: First-line (1L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3F: Second-line (2L) gastric/gastroesophageal cancer · CR-001 Dose Expansion 3G: First-line (1L) Biliary tract cancer

    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07335497
Lead sponsor
Crescent Biopharma, Inc.
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Feb 17, 2026
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Crescent Clinical Trials
Contact
clinicaltrials@crescentbiopharma.com
617-430-5595
Brad Sumrow, MD
study director · Crescent Biopharma, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001

Start the discussion